1LOFBERG M, TAHTELA R, HARKONEN M, et al.Myosin heavy-chain fragments and cardiac troponins in the serum in rhabdomyolysis diagnostic specificity of new biochemical markers [J]. Arch Neurol, 1995, 52 ( 12 ):1210-1214.
2WU A H, LANE P L. Metaanalysis in clinical chemistry:validation of cardiac troponin T as a marker for ischemic heart diseases[J]. Clin Chem,1995,41 (8) : 1228-1233.
4MULLER B M, HALLERMAYER K, SCHRODER A,et al. Improved troponin TELISA specific for cardiac troponin T isoform:assay development and clinical validation[J]. Clin Chem, 1997,43(37) :458-466.
二级参考文献10
1Apple FS, Christenson RH, Valdes R Jr, et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem, 1999, 45(2): 199-205.
2Swaanenburg JC, Loef BG, Volmer M, et al. Creatine kinase MB, troponin I, and troponin T release patterns after coronary artery bypass grafting with or without cardiopulmonary bypass and after aortic and mitral valve surgery. Clin Chem, 2001, 47(3): 584-587.
3Ferrieres G, Calzolari C, Mani JC, et al. Human cardiac troponin I: precise identification of antigenic epitopes and prediction of secondary structure. Clin Chem, 1998, 44(3): 487-493.
4Hafner G, Peetz D, Dati F, et al. Analytical and clinical evaluation of troponin I determination on dimension RXL-HM. Clin Chem Lab Med, 2000, 38(4): 355-361.
5Heeschen C, Goldmann BU, Moeller RH, et al. Analytical performance and clinical application of a new rapid bedside assay for the detection of serum cardiac troponin I. Clin Chem, 1998, 44(9): 1925-1930.
7Kao JT, Wong IL, Lee JY, et al. Comparison of Abbott AxSYM, Behring Opus Plus, DPC Immulite and OrthoClinical Diagnostics Vitros ECi for measurement of cardiac troponin I. Ann Clin Biochem, 2001, 38(Pt 2): 140-146.
8Lin JC, Apple FS, Murakami MM, et al. Rates of positive cardiac troponin I and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes. Clin Chem, 2004, 50(2): 333-338.
